Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff

BARCELONA, Spain, May 2, 2011 /PRNewswire/ -- Grifols, S.A. ("Grifols") and Talecris Biotherapeutics Holdings Corporation ("Talecris"), announced today that they have signed a "Consent Agreement" with the Staff of the Bureau of Competition of the US Federal Trade Commission (FTC) by means of which the conditions for the merger transaction between both companies are agreed.  The Consent Agreement is subject to approval of the FTC Commissioners, who will be reviewing the matter.

To satisfy the Consent Agreement conditions, Grifols has signed agreements for the sale of assets and entered into certain commercial, lease and manufacturing agreements with the Italian company Kedrion, for up to seven (7) years. 

These agreements refer to four main areas: 

  • Kedrion and Grifols enter into a contract manufacturing agreement to fractionate and purify Kedrion's plasma to deliver IVIG and Albumin under Kedrion's private label, and Factor VIII under the trade name Koate, all of them for sale only in the US.
  • Grifols sells to Kedrion the Melville fractionation facility. Grifols will manage the facility for up to a four-year period under a lease agreement with Kedrion.
  • Grifols sells to Kedrion the Talecris' FVIII US business (Koate).
  • Grifols sells to Kedrion two Plasma Collection Centers.

Grifols states that neither the Consent Agreement nor the agreements signed with Kedrion will affect the operating synergies that Grifols expects to achieve at the combined company with the merger transaction. 

About Grifols

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and it is included in the Ibex-35. Grifols is the leading European plasma products company, and the fourth-largest producer in the world.  The company has implemented an ambitious investment plan to enable it to deliver sustained growth over the next 8 to 10 years.  For more information please visit:  www.grifols.com

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: http://www.talecris.com/

About Kedrion

Kedrion is active in the development, production and distribution of plasma-derived pharmaceutical products used in treating patients affected by haemophilia, immune deficiency, coagulation disorders and other forms of serious diseases. Kedrion, founded in 2001 as business combination of family owned companies, is the Italian leader in the sector and sells in 40 countries around the world. Headquartered in Italy (Castelvecchio Pascoli, near Lucca), Kedrion has two production plants in Italy, in Bolognana and in S. Antimo, and one in Hungary, in Godollo. Kedrion has also 12 plasma collection centers, in the US, Germany and Hungary.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.